HGH Fragment 176-191

weak data

Also seen as: HGH frag, frag 176-191, HGH Frag 176-191, Fragment 176-191

The Dose Guy’s verdict

Sep 1, 2026
1 source

The marketing was always better than the evidence. HGH fragment 176-191 is the tail end of growth hormone, sold as the part that burns fat without the growth effects, and the story sounds clean until you look for the data behind it. No published human fat-loss trials, no animal weight-loss studies. Its modified descendant, AOD-9604, made it to phase 2 human obesity trials and never published a result. If you want fat loss with receipts behind it, the incretins have thousands of participants and outcomes you can hold.

Would I take it?Not for me, the evidence trail is too cold.

What it is

Amino acids 176 through 191 of human growth hormone, the C-terminal fragment identified decades ago as carrying lipolytic activity, the ability to mobilize fat from storage, without triggering IGF-1 or the growth signaling that makes full HGH a complicated tool. AOD-9604 is a modified form, amino acids 177 through 191 with an added N-terminal tyrosine, and it’s the one that actually went through clinical development for obesity. The fragment itself never got that far in published research. Vendors have sold it for years on the strength of the mechanism story and the implied connection to growth hormone, but the PubMed trail for fat loss is empty.

What the research shows

No human trials. Zero. Everything below is animal or in-vitro work. Read it as “interesting,” not “evidence it works in you.”

The published evidence for this fragment, specifically for fat loss, is effectively nothing. The only PubMed entry is a nanoparticle study that used the fragment as a targeting molecule for breast-cancer cells:

The sole published study used HGH fragment 176-191 as a docking ligand in a doxorubicin nanoparticle aimed at MCF-7 breast-cancer cells. It tells you nothing about fat loss.DDDT 2022 · in silico + cell line

No human treatment trial of HGH fragment 176-191 exists in the literature.as of Aug 2026

No human pharmacokinetic study exists. Nobody has published how this fragment absorbs, distributes, or clears in a person.as of Aug 2026

Realistic protocols

There’s nothing to build a protocol from. No human dose, no absorption curve, no safety profile. The community runs 250 to 500 mcg subcutaneously, twice daily, typically fasted and around training, and that protocol is forum lore passed hand to hand. If you run it, you’re paying for a peptide whose own modified version went to human trials and never published a result. For actual fat loss with data behind it, tirzepatide, semaglutide, and retatrutide have thousands of participants and published outcomes.